Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041856 | 1.00 | ADRA2A (0.33) | ADRA2AADRA1ATDP1PSMB8PSMB5 | |
| SCHEMBL141048 | 0.95 | ADRA2A (0.36) | ADRA2AADRA1ATDP1PSMB8PSMB5 | |
| SCHEMBL28680314 | 0.94 | EPHX2 (0.34) | ADRA2AADRA1ATDP1PSMB8PSMB5 | |
| SCHEMBL21706405 | 0.94 | PSMB8 (0.32) | ADRA2AADRA1ATDP1PSMB8PSMB5 | |
| SCHEMBL13821165 | 0.94 | ALOX12 (0.35) | ADRA2AADRA1ATDP1PSMB8PSMB5 | |
| SCHEMBL9972409 | 0.93 | DGKA (0.41) | TDP1PSMB8PSMB5MAPTALOX12 | |
| SCHEMBL9972406 | 0.93 | DGKA (0.37) | TDP1PSMB8PSMB5MAPTALOX12 | |
| SCHEMBL16214307 | 0.92 | SMN1; SMN2 (0.37) | ADRA2AADRA1APSMB8PSMB5MAPT | |
| SCHEMBL17637586 | 0.92 | DGKA (0.43) | TDP1PSMB8PSMB5ALOX12DGKA | |
| SCHEMBL26210568 | 0.91 | THRB (0.31) | PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | INSERT THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9550860-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550860-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9393344-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110179-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ADRA2A 1599/4885ADRA1A 1090/4885TDP1 879/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ADRA2A 1599/4885ADRA1A 1090/4885TDP1 879/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | ADRA2A 3037/4885ADRA1A 2651/4885TDP1 2670/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ADRA2A 1599/4885ADRA1A 1090/4885TDP1 879/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | ADRA2A 1596/4885ADRA1A 907/4885TDP1 2471/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | ADRA2A 4830/4885ADRA1A 4863/4885TDP1 2231/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | ADRA2A 2911/4885ADRA1A 2308/4885TDP1 2230/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | ADRA2A 4800/4885ADRA1A 4832/4885TDP1 2716/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | ADRA2A 4352/4885ADRA1A 4472/4885TDP1 1801/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | ADRA2A 2464/4885ADRA1A 2164/4885TDP1 1095/4885 |
| US-20170369651-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | ADRA2A 1958/4885ADRA1A 1145/4885TDP1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.